Pear Therapeutics EBIT

Pear Therapeutics (PEAR) currently reports a EBIT of $-120M as of December 2022. That compares with $-36M in the prior-year period — down 241.4% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore Pear Therapeutics's EBIT history and peer comparisons.

Pear Therapeutics's EBIT decreased from $-36M to $-120M — a 241.4% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pear Therapeutics's EBIT of $-120M is lower than the its sector sector average of $-6.4M. That is roughly 1826.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Pear Therapeutics reported $-120M in EBIT as of December 2022. That compares with $-36M in the prior-year period — down 241.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-120M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for Pear Therapeutics, and consider following PEAR for alerts when major investors trade the stock.